Lattice Expands mVision Solutions Stack Capabilities
2.3.2021 00:00:00 EET | Business Wire | Press release
Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, launched the latest version of its award-winning solutions stack for low power embedded vision systems, Lattice mVision™ 2.0. The new version features multiple updates that further accelerate the design of embedded vision applications for industrial, automotive, medical, and smart consumer systems. It includes support for popular new image sensors used in industrial and automotive systems and a new image signal processing IP core and reference design to help developers design smart vision applications at the Edge. The stack also includes support for the Lattice Propel™ design environment to simplify development of vision systems with an embedded RISC-V processor.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210301005142/en/
The Lattice mVision solutions stack is a comprehensive collection of modular hardware platforms, IP building blocks, easy-to-use FPGA design tools, reference designs, and custom design services that simplify and accelerate the development of embedded vision systems. (Graphic: Business Wire)
The COVID-19 pandemic and the drive to improve safety and efficiency is accelerating the need for industrial companies to incorporate smart embedded vision technology in their systems to support human presence detection, touchless HMI, and enhanced AR/VR capabilities, while simultaneously striving to improve manufacturing quality and throughput by leveraging intelligent machine vision technology. According to Allied Market Research, “the global machine vision system market size was valued at $29.7 billion in 2019, and is projected to reach $74.9 billion by 2027, registering a CAGR of 11.3% from 2020 to 2027.”1
“Lattice CrossLink-NX devices with integrated hard MIPI support and low power consumption are ideal for camera applications operating at the Edge. Using CrossLink-NX with an embedded RISC-V processor enables a more compact and efficient ISP implementation,” said Arndt Bussman, CTO at Helion. “We applaud Lattice for its ongoing work to enhance their mVision solutions stack, and we’re pleased to partner with Lattice to provide optimized ISP solutions to the industry.”
“Lattice solutions stacks make it easier for customers to adopt emerging technologies by providing a comprehensive collection of ready-to-use software, IP, hardware demos, and reference designs that help them quickly deploy applications like embedded vision in current and future product designs,” said Mark Hoopes, Director of Industrial Segment Marketing, Lattice Semiconductor. “The updates announced today expand the potential use cases for mVision by broadening support for popular image sensors used in industrial and automotive markets, simplifying hardware and software design with our drag-and-drop Propel design environment, and adding development boards and reference designs powered by our flagship FPGA for embedded vision, CrossLink-NX.”
Key updates to the Lattice mVision solutions stack include:
- Expanded support for automotive, industrial, and medical embedded vision applications – Lattice added new development boards supporting popular image sensors for industrial and medical applications to the mVision stack. Image sensors supported include the Sony IMX464 and IMX568 and the AR0344CS from ON Semiconductor.
- Support for Lattice Propel Design Environment – Propel is a design environment for accelerating embedded processor-based development on low power, small form factor Lattice FPGAs. The tool includes a complete set of graphical and command-line tools to create, analyze, compile, and debug both the hardware design of an FPGA-based processor system, and the software design for that processor system.
- New Lattice ISP reference design - Expands Lattice’s mVision solution options for customers, enabling increased adoption while demonstrating our commitment to our customers.
For more information about the Lattice products mentioned above, please visit:
About Lattice Semiconductor
Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing communications, computing, industrial, automotive, and consumer markets. Our technology, long-standing relationships, and commitment to world-class support lets our customers quickly and easily unleash their innovation to create a smart, secure and connected world.
For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, Twitter, Facebook, YouTube, WeChat, Weibo or Youku.
Lattice Semiconductor Corporation, Lattice Semiconductor (& design) and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.
GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210301005142/en/
Contact information
MEDIA CONTACT:
Bob Nelson
Lattice Semiconductor
408-826-6339
Bob.Nelson@latticesemi.com
INVESTOR CONTACT:
Rick Muscha
Lattice Semiconductor
408-826-6000
Rick.Muscha@latticesemi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom